Exagen inc. reports strong fourth quarter and full-year 2024 results and business highlights

Delivered record full-year total revenue and avise ctd average selling price improved full-year adjusted ebitda loss and cash use by over 40% commercialized new biomarkers to enhance clinical utility of avise ctd carlsbad, calif., march 11, 2025 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended december 31, 2024, and recent business highlights.
XGN Ratings Summary
XGN Quant Ranking